安贝尼妥单抗联合化疗二线治疗HER2阳性胃癌的III期期中分析
KC-WISE研究是在中国51家中心开展的随机双盲III期试验,纳入188例曲妥珠单抗治疗失败的HER2阳性胃/胃食管结合部腺癌患者,按1:1随机接受安贝尼妥单抗30 mg/kg或安慰剂联合化疗。预设期中分析显示,安贝尼妥单抗组独立评审委员会评估的中位无进展生存期(7.1个月 vs 2.7个月,HR 0.25,95%CI 0.17-0.39,P<0.0001)和总生存期(19.6个月 vs 11.5个月,HR 0.29,95%CI 0.17-0.50,P<0.0001)均显著优于单纯化疗。
要点
- 曲妥珠单抗治疗失败的HER2阳性胃/胃食管结合部腺癌患者中,安贝尼妥单抗联合化疗较单纯化疗显著改善PFS和OS。
- 安贝尼妥单抗组≥3级治疗相关不良事件发生率为60%,以中性粒细胞减少(30%)最常见。
- 安贝尼妥单抗组未报告治疗相关死亡,对照组报告5例,需关注安全性差异。
核心结论
- 在曲妥珠单抗治疗失败的HER2阳性胃/胃食管结合部腺癌患者中,安贝尼妥单抗联合化疗较单纯化疗显示出具有临床意义的PFS和OS优势,但需最终分析确认。
研究设计与样本
- 多中心、随机、双盲、III期试验,在中国51家医院开展,共纳入188例患者,按1:1随机分配至安贝尼妥单抗组(n=95)或对照组(n=93)。
- 安贝尼妥单抗30 mg/kg或安慰剂每3周一次,联合化疗(紫杉醇175 mg/m²或多西他赛75 mg/m²第1天,或伊立替康125 mg/m²第1、8天,21天为一周期),按联合化疗类型、HER2表达状态和既往治疗线数分层。
- 主要终点为独立评审委员会评估的意向治疗人群PFS和OS,预设期中分析触发条件为观察到约120例PFS事件。
主要发现
- 安贝尼妥单抗组中位PFS为7.1个月(95%CI 5.5-10.3),对照组为2.7个月(95%CI 1.5-3.0),HR 0.25(95%CI 0.17-0.39),P<0.0001。
- 安贝尼妥单抗组中位OS为19.6个月(95%CI 15.0个月-不可评估),对照组为11.5个月(95%CI 6.5-14.4),HR 0.29(95%CI 0.17-0.50),P<0.0001。
- 安贝尼妥单抗组≥3级治疗相关不良事件发生率为60%(56/94),对照组为45%(42/93);最常见为中性粒细胞减少(30% vs 22%)和白细胞减少(21% vs 25%)。
- 治疗相关死亡在安贝尼妥单抗组为0例,对照组为5例。
临床怎么用
- 对于曲妥珠单抗治疗失败的HER2阳性胃/胃食管结合部腺癌患者,安贝尼妥单抗联合化疗可作为潜在治疗选择,但需等待最终分析结果确认。
- 治疗期间应密切监测≥3级治疗相关不良事件,尤其是中性粒细胞减少和白细胞减少。
局限性
- 本次为预设期中分析,结论需最终分析确认。
- 研究仅在中国51家医院开展,人群代表性可能受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gastric cancer after progression on trastuzumab treatment remains an unmet therapeutic challenge and is associated with suboptimal progression-free survival (PFS) and overall survival (OS). PATIENTS AND METHODS: This multicenter, randomized, double-blind, phase III trial was conducted at 51 hospital sites in China. Patients with HER2-positive gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma whose previous therapy containing trastuzumab had failed were randomized (1 : 1) to receive anbenitamab 30 mg/kg or placebo every 3 weeks, in combination with chemotherapy (paclitaxel 175 mg/m2 or docetaxel 75 mg/m2 on day 1 of a 21-day cycle, or irinotecan 125 mg/m2 on day 1 and 8 of a 21-day cycle), stratified by combined chemotherapy [taxane (paclitaxel or docetaxel) or irinotecan], HER2 expression [immunohistochemistry (IHC) 3+ or IHC 2+/FISH+], and previous lines of therapy (1 or ≥2). Primary endpoints were independent review committee-assessed PFS and OS in the intention-to-treat population. This interim analysis was planned when ∼120 PFS events were observed. RESULTS: A total of 188 patients were enrolled and assigned to receive anbenitamab plus chemotherapy (anbenitamab group, n = 95) or chemotherapy alone (control group, n = 93). At the prespecified interim analysis, anbenitamab plus chemotherapy significantly improved PFS [median 7.1 months, 95% confidence interval (CI) 5.5-10.3 months versus 2.7 months, 95% CI 1.5-3.0 months; hazard ratio (HR), 0.25, 95% CI 0.17-0.39, P < 0.0001] and OS (median 19.6 months, 95% CI 15.0 months to not evaluable versus 11.5 months, 95% CI 6.5-14.4 months; HR 0.29, 95% CI 0.17-0.50, P < 0.0001) compared with chemotherapy alone. Grade 3 or higher treatment-related adverse events occurred in 56 (60%) of 94 patients who received anbenitamab plus chemotherapy and 42 (45%) of 93 patients who received chemotherapy alone, with neutropenia (30% versus 22%) and leukopenia (21% versus 25%) being most common. Treatment-related deaths were reported in 0 and 5 patients in the anbenitamab and control groups, respectively. CONCLUSIONS: Compared with chemotherapy alone, anbenitamab plus chemotherapy demonstrated clinically meaningful superior PFS and OS in patients with HER2-positive GC/GEJ adenocarcinoma whose previous therapy containing trastuzumab had failed. These findings warrant confirmation in the final analysis.
引用
- Liu R, Zhao J, Zhang R, et al. Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial. Ann Oncol. 2026. PMID: 41571045. doi:10.1016/j.annonc.2026.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。